-DOCSTART- -X- O
Antiviral -X- _ O
monoclonal -X- _ O
antibodies -X- _ O
( -X- _ O
mAbs -X- _ O
) -X- _ O
represent -X- _ O
promising -X- _ O
therapeutics. -X- _ O
However -X- _ O
, -X- _ O
most -X- _ O
mAbs- -X- _ B-Intervention
based -X- _ I-Intervention
immunotherapies -X- _ I-Intervention
conducted -X- _ O
so -X- _ O
far -X- _ O
have -X- _ O
only -X- _ O
considered -X- _ O
the -X- _ O
blunting -X- _ O
of -X- _ O
viral -X- _ O
propagation -X- _ O
and -X- _ O
not -X- _ O
other -X- _ O
possible -X- _ O
therapeutic -X- _ O
effects -X- _ O
independent -X- _ O
of -X- _ O
virus -X- _ O
neutralization -X- _ O
, -X- _ O
namely -X- _ O
the -X- _ O
modulation -X- _ O
of -X- _ O
the -X- _ O
endogenous -X- _ O
immune -X- _ O
response. -X- _ O
As -X- _ O
induction -X- _ O
of -X- _ O
long-term -X- _ O
antiviral -X- _ O
immunity -X- _ O
still -X- _ O
remains -X- _ O
a -X- _ O
paramount -X- _ O
challenge -X- _ O
for -X- _ O
treating -X- _ O
chronic -X- _ O
infections -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
asked -X- _ O
here -X- _ O
whether -X- _ O
neutralizing -X- _ B-Intervention
mAbs -X- _ I-Intervention
can -X- _ O
, -X- _ O
in -X- _ O
addition -X- _ O
to -X- _ O
blunting -X- _ O
viral -X- _ O
propagation -X- _ O
, -X- _ O
exert -X- _ O
immunomodulatory -X- _ O
effects -X- _ O
with -X- _ O
protective -X- _ O
outcomes. -X- _ O
Supporting -X- _ O
this -X- _ O
idea -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
here -X- _ O
that -X- _ O
mice -X- _ B-Patient
infected -X- _ I-Patient
with -X- _ I-Patient
the -X- _ I-Patient
FrCas -X- _ I-Patient
( -X- _ I-Patient
E -X- _ I-Patient
) -X- _ I-Patient
murine -X- _ I-Patient
retrovirus -X- _ I-Patient
on -X- _ I-Patient
day -X- _ I-Patient
8 -X- _ I-Patient
after -X- _ I-Patient
birth -X- _ I-Patient
die -X- _ B-Outcome
of -X- _ I-Outcome
leukemia -X- _ I-Outcome
within -X- _ I-Outcome
4–5 -X- _ I-Outcome
months -X- _ I-Outcome
and -X- _ I-Outcome
mount -X- _ I-Outcome
a -X- _ I-Outcome
non-protective -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
those -X- _ I-Outcome
rapidly -X- _ I-Outcome
subjected -X- _ I-Outcome
to -X- _ I-Outcome
short -X- _ I-Outcome
immunotherapy -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
neutralizing -X- _ I-Outcome
mAb -X- _ I-Outcome
survive -X- _ I-Outcome
healthy -X- _ I-Outcome
and -X- _ I-Outcome
mount -X- _ I-Outcome
a -X- _ I-Outcome
long-lasting -X- _ I-Outcome
protective -X- _ I-Outcome
antiviral -X- _ I-Outcome
immunity -X- _ I-Outcome
with -X- _ I-Outcome
strong -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses. -X- _ I-Outcome
Interestingly -X- _ O
, -X- _ O
the -X- _ O
administered -X- _ B-Intervention
mAb -X- _ I-Intervention
mediates -X- _ O
lysis -X- _ O
of -X- _ O
infected -X- _ O
cells -X- _ O
through -X- _ O
an -X- _ O
antibody-dependent -X- _ O
cell -X- _ O
cytotoxicity -X- _ O
( -X- _ O
ADCC -X- _ O
) -X- _ O
mechanism. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
it -X- _ O
forms -X- _ O
immune -X- _ O
complexes -X- _ O
( -X- _ O
ICs -X- _ O
) -X- _ O
with -X- _ O
infected -X- _ O
cells -X- _ O
that -X- _ O
enhance -X- _ O
antiviral -X- _ O
CTL -X- _ O
responses -X- _ O
through -X- _ O
FcγR-mediated -X- _ O
binding -X- _ O
to -X- _ O
dendritic -X- _ O
cells -X- _ O
( -X- _ O
DCs -X- _ O
) -X- _ O
. -X- _ O
Importantly -X- _ O
, -X- _ O
the -X- _ O
endogenous -X- _ B-Outcome
antiviral -X- _ I-Outcome
antibodies -X- _ I-Outcome
generated -X- _ O
in -X- _ O
mAb-treated -X- _ B-Patient
mice -X- _ I-Patient
also -X- _ O
display -X- _ O
the -X- _ O
same -X- _ O
properties -X- _ O
, -X- _ O
allowing -X- _ O
containment -X- _ O
of -X- _ O
viral -X- _ O
propagation -X- _ O
and -X- _ O
enhancement -X- _ O
of -X- _ O
memory -X- _ O
cellular -X- _ O
responses -X- _ O
after -X- _ O
disappearance -X- _ O
of -X- _ O
the -X- _ O
administered -X- _ B-Intervention
mAb. -X- _ I-Intervention
Thus -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
neutralizing -X- _ B-Intervention
antiviral -X- _ I-Intervention
mAbs -X- _ I-Intervention
can -X- _ O
act -X- _ O
as -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
capable -X- _ O
of -X- _ O
stimulating -X- _ B-Outcome
a -X- _ I-Outcome
protective -X- _ I-Outcome
immunity -X- _ I-Outcome
lasting -X- _ I-Outcome
long -X- _ I-Outcome
after -X- _ O
the -X- _ O
end -X- _ O
of -X- _ O
the -X- _ O
treatment. -X- _ O
They -X- _ O
also -X- _ O
show -X- _ O
an -X- _ O
important -X- _ B-Outcome
role -X- _ I-Outcome
of -X- _ I-Outcome
infected-cells -X- _ I-Outcome
/ -X- _ I-Outcome
antibody -X- _ I-Outcome
complexes -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
induction -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
maintenance -X- _ I-Outcome
of -X- _ I-Outcome
protective -X- _ I-Outcome
immunity -X- _ I-Outcome
through -X- _ I-Outcome
enhancement -X- _ I-Outcome
of -X- _ I-Outcome
both -X- _ I-Outcome
primary -X- _ I-Outcome
and -X- _ I-Outcome
memory -X- _ I-Outcome
antiviral -X- _ I-Outcome
T-cell -X- _ I-Outcome
responses. -X- _ I-Outcome
They -X- _ O
also -X- _ O
indicate -X- _ O
that -X- _ O
targeting -X- _ B-Outcome
infected -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
not -X- _ I-Outcome
just -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
by -X- _ I-Outcome
antibodies -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
crucial -X- _ I-Outcome
for -X- _ I-Outcome
elicitation -X- _ I-Outcome
of -X- _ I-Outcome
efficient -X- _ I-Outcome
, -X- _ I-Outcome
long-lasting -X- _ I-Outcome
antiviral -X- _ I-Outcome
T-cell -X- _ I-Outcome
responses. -X- _ I-Outcome
This -X- _ O
must -X- _ O
be -X- _ O
considered -X- _ O
when -X- _ O
designing -X- _ O
antiviral -X- _ B-Intervention
mAb-based -X- _ I-Intervention
immunotherapies -X- _ I-Intervention
. -X- _ O

